Vigonvita Life Sciences Co Ltd

Vigonvita Life Sciences Co., Ltd. is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs for neuropsychiatry, reproductive health, and viral infections. Its pipeline includes LV232, a dual-target 5-HTT/5-HT modulator in Phase II for depressive disorder, and TPN171, a phosphodiesterase type 5 inhibitor that completed Phase III for erectile dysfunction. The company also develops VV116, an RNA-dependent RNA polymerase inhibitor that completed Phase II for respiratory syncytial virus and COVID-19 infections, along with earlier-stage candidates such as TPN102 for epilepsy, VV119 for psychiatric disorders and schizophrenia, and VV261 for chikungunya, coronaviruses, influenza, and arena virus. Incorporated in 2013, it is headquartered in Suzhou, China.